Sex with cialis

Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials.
Objective: To determine whether patients with erectile dysfunction (ED) and treated with tadalafil use the 36-h duration of effect of the drug, and to discern if the timing of intercourse attempts is influenced by patient age, baseline severity of ED, or previous experience with sildenafil citrate.
Patients and methods: In 11 multicentre, double-blind, placebo-controlled studies, 2102 patients with ED were randomized to a maximum of one dose per day of tadalafil 10 or 20 mg (1464 men), or placebo (638 men) with no time restrictions before attempting sexual activity after the dose. A post hoc analysis was used to determine the proportion of men with ED who attempted sexual intercourse during various intervals (>0 to 1 to 4 to 12 to.
Results: Of patients in different age groups and various ED severity, > or = 79% and > or = 53% chose to attempt sexual intercourse at least once during the 12-week treatment period at 4-36 and 12-36 h, respectively, after taking tadalafil. Regardless of previous experience with sildenafil, about a third of patients using tadalafil attempted intercourse a mean of at least once per week at 4-36 h after the dose over 12 weeks. Furthermore, 58% of patients attempted intercourse at least once during two intervals (>1 to 12 to.
Conclusion: Regardless of age, ED severity, or previous experience with sildenafil, most patients attempted sexual intercourse at least once at 12-36 h after one dose of tadalafil over a 12-week treatment period. Furthermore, by engaging in sexual intercourse at both earlier and later intervals after separate doses, most patients on treatment did not adhere to a fixed schedule of intimacy and thus took advantage of the 36-h duration.
Similar articles.
Eardley I, Montorsi F, Jackson G, Mirone V, Chan ML, Loughney K, Vail GM, Beardsworth A. Eardley I, et al. BJU Int. 2007 Jul;100(1):122-9. doi: 10.1111/j.1464-410X.2007.06916.x. BJU Int. 2007. PMID: 17552960 Clinical Trial.
Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley CM Jr, Hague JA, Ahuja S. Young JM, et al. J Androl. 2005 May-Jun;26(3):310-8. doi: 10.2164/jandrol.04126. J Androl. 2005. PMID: 15866997 Clinical Trial.
Rosen RC, Shabsigh R, Kuritzky L, Wang WC, Sides GD. Rosen RC, et al. Curr Med Res Opin. 2005 Nov;21(11):1701-9. doi: 10.1185/030079905X65538. Curr Med Res Opin. 2005. PMID: 16307689.
Mulhall JP, Levine LA, Jünemann KP. Mulhall JP, et al. Urology. 2006 Sep;68(3 Suppl):17-25. doi: 10.1016/j.urology.2006.05.041. Urology. 2006. PMID: 17011372 Review.
Nusbaum MR. Nusbaum MR. J Am Osteopath Assoc. 2004 Mar;104(3 Suppl 4):S2-5. J Am Osteopath Assoc. 2004. PMID: 15083992 Review.
Cited by.
Sadovsky R, Brock GB, Gutkin SW, Sorsaburu S. Sadovsky R, et al. Int J Clin Pract. 2009 Aug;63(8):1214-30. doi: 10.1111/j.1742-1241.2009.02119.x. Int J Clin Pract. 2009. PMID: 19624789 Free PMC article. Review.
Frajese GV, Pozzi F, Frajese G. Frajese GV, et al. Clin Interv Aging. 2006;1(4):439-49. doi: 10.2147/ciia.2006.1.4.439. Clin Interv Aging. 2006. PMID: 18046921 Free PMC article. Review.
Publication types.